[G25-03] Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Addendum to Project A24-85
Last updated 15.04.2025
Project no.:
G25-03
Commission:
Commission awarded on 07.01.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Head and nerves
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
The current version 1.1 of the addendum replaces version 1.0 published on Feb 20, 2025.
DOI:
https://doi.org/10.60584/G25-03_V1.1
| Project no. | Title | Status |
|---|---|---|
| A24-85 | Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-02-20 A G-BA decision was published.